Not the Usual Suspects: FDA Seeks New Advisors for Risk Communication Committee

The Food & Drug Administration is bringing a whole new constituency into the advisory committee process with the creation of an expert panel focused on improving the way the agency communicates risk information to the public. For industry, success will require even greater attention to foresee and address safety issues.

The Food & Drug Administration is bringing a whole new constituency into the advisory committee process with the creation of an expert panel focused on improving the way the agency conveys risk information to the public.

The creation of the Risk Communication Advisory Committee is the latest in FDA’s measured rollout of many of the Institute...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Agency Leadership

More from Pink Sheet

EU Fines Alchem Over Buscopan API Cartel

 
• By 

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

Bayesian Statistics In EU Clinical Trials: EMA Discusses Balancing Efficiency With Rigor

 

Bayesian statistics could help clinical trial sponsors to include external information in their analyses, but concerns around bias and incorrect conclusions remain, the European Medicines Agency said.

Korea Pre-Review Consultations Help Accelerate R&D

 
• By 

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.